# **ORA-Sweet**<sup>®</sup>

# Flavored Syrup Vehicle



ORA-Sweet is a syrup vehicle used to simplify the process of flavoring and sweetening extemporaneous compounded oral preparations. ORA-Sweet allows the pharmacist to formulate elegant, sweetened products with minimum time and maximum dependability. ORA-Sweet is the modern version of simple syrup flavored with a citrus-berry blend for a highly palatable taste.

## **Applications**

ORA-Sweet may be used alone or in combination with other agents. ORA-Sweet will retain its flavoring properties when diluted up to 50% with water or suspending agents. Its versatility makes it ideal for the flavoring of:

- Pediatric suspensions
- · Geriatric suspensions

### How to Use

ORA-Sweet is the ideal flavoring and sweetening agent for many suspensions, but it is specially formulated to complement Perrigo's suspending vehicle ORA-Plus<sup>®</sup>. ORA-Sweet and ORA-Plus can be combined in a 50/50 ratio to produce a pleasant tasting elegant suspension.

### **Properties**

ORA-Sweet contains sucrose which acts as a sweetening agent. Small amounts of glycerin and sorbitol are added to prevent "cap lock" problems common to most syrups. Its flavoring agents help increase palatability. ORA-Sweet is buffered to a slightly acidic pH to help diminish degradation of medicinal agents through oxidation.

## **Contains:**

Purified water, sucrose, glycerin, sorbitol, and berry citrus flavor (contains FD&C Red #40). Buffered with citric acid and sodium phosphate. Preserved with methylparaben and potassium sorbate.

## **Specifications**

Appearance: Clear liquid with a slight tint pH: Approximately 4.3 Taste: Sweet citrus-berry flavor Osmolality: 4109 mOsm/kg

Available through your wholesaler or distributor.



# **ORA-Sweet**<sup>®</sup>

## **Compounding Examples**



#### CHLOROQUINE PHOSPHATE 15 mg/mL, 100 mL<sup>2</sup>

Chloroquine Phosphate 500 mg/tablet	3 tablets
ORA-Plus	50 mL
ORA-Sweet*	q.s. 100 mL

- Expiration 60 days
- Protect from light
- Shake well before using

#### METOLAZONE 1 mg/mL, 120 mL<sup>1</sup>

Metolazone 10 mg/tablet	12 tablets
ORA-Plus	60 mL
ORA-Sweet*	q.s. 120 mL
<ul> <li>Expiration 60 days</li> </ul>	

- Protect from light
- Shake well before using

#### PROCAINAMIDE HCI 50 mg/mL, 120 mL<sup>1</sup>

Procainamide HCI 250 mg/capsule	24 capsules
ORA-Plus	60 mL
ORA-Sweet*	q.s. 120 mL
<ul> <li>Expiration 60 days</li> </ul>	

- Protect from light
- · Shake well before using

#### KETOCONAZOLE 20 mg/mL, 120 mL<sup>1</sup>

Ketoconazole 200 mg/tablet	12 tablets
ORA-Plus	60 mL
ORA-Sweet*	q.s. 120 mL
<ul> <li>Expiration 60 days</li> </ul>	

- Protect from light
- · Shake well before using

#### METRONIDAZOLE 50 mg/mL, 120 mL<sup>1</sup>

Metronidazole powder	6 grams
ORA-Plus	60 mL
ORA-Sweet*	q.s. 120 mL
<ul> <li>Expiration 60 days</li> </ul>	
<ul> <li>Destaut formell'add.</li> </ul>	

- Protect from light
- Shake well before using

#### SPIRONOLACTONE 25 mg/mL, 120 mL<sup>1</sup>

Spironolactone 25 mg/tablet	120 tablets
ORA-Plus	60 mL
ORA-Sweet*	q.s. 120 mL
<ul> <li>Expiration 60 days</li> </ul>	
<ul> <li>Protect from light</li> </ul>	

- Shake well before using

# General Directions for Compounding ORA-Sweet\*/ORA-Plus Suspensions

# ORA-Sweet and ORA-Plus should be combined in a 50/50 ratio to achieve optimal formulation.

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) *It may be wise to add approximately 10% overage for compounding losses.*
- Crush tablets with a mortar and pestle to a <u>fine</u> powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of ORA-Plus and triturate to a thick, <u>smooth</u> paste. Add the remainder of the ORA-Plus by geometric dilution. *The amount of* ORA-Plus should be 50% of the total solution.
- Bring the suspension to a final volume using ORA-Sweet\*. Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. *If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.*
- Depending on the medicinal agent used, label containers "Shake Well Before Using", "Protect From Light", and "Keep Refrigerated".
- \*ORA-Sweet may be substituted with ORA-Sweet SF. Both products may be used in a 1:1 ratio with ORA-Plus. <sup>1</sup>American Journal of Health-System Pharmacists 1996: 53:2073-8.

<sup>2</sup>American Journal of Health-System Pharmacists 1998; 55:1915-20.

#### Contraindications

 $\mathsf{ORA}\text{-}\mathsf{Sweet}$  is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

#### DISCLAIMER:

All information presented is intended to demonstrate the application of Perrigo vehicles in compounding. The information and examples provided in this paper have not been evaluated by the Food and Drug Administration and are provided for educational purposes only. Any information and examples provided are not intended to replace the advice of a physician or take the place of good pharmaceutical compounding practices. The preparation, dispensing, and administration of pharmaceuticals is the responsibility of licensed medical professionals and must adhere to current pharmaceutical compounding requirements and lawful practice of medicine. Perrigo assumes no liability for any injury and/or damage to persons from use of any information and/or examples contained in this document. Perrigo does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process. Vehicle purchasers assume all risks of patent infringement by reason of any such use, combination or operation. Before compounding any prescription drug with Perrigo vehicles, please review the full prescribing information of the prescription drug for important safety information and limitations of use

© 2019 Perrigo Company, plc 3X8-AID01-ver01-01 Trademarks held by their respective owners.

